Robert Nelsen

This profile gathers the share dealings of Robert Nelsen across 5 companies, led by Vir Biotechnology, Inc., Sana Biotechnology, Inc. and Prime Medicine, Inc. Over a trading history stretching from 22 March 2021 to 1 August 2025, the count stands at 28 filings.

No open-market sale appears; the market trades are 3 purchases worth €29.2M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 9 share grants. So far in 2025, the count stands at 1 purchase and no sales.

The median purchase comes to €8.8M. Of 3 purchases, 3 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 1 August 2025 with an open-market purchase (€8.8M) in Prime Medicine, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.